Since individuals with pathogenic LRRK2 mutations are more likely to develop PD than the general population, it may be important to establish cohorts based on genetic testing for prospective clinical/biomarker studies of asymptomatic LRRK2 mutation carriers and clinical trials for secondary prevention once a potential disease-modifying therapy becomes available. The gene discussed is LRRK2; the disease is Parkinson disease.